What we say:
Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene
From the Significance of the study to Public health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over 80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.
From research findings to therapeutic opportunity:
This study suggests, for the first time, that a therapeutic mix encompassing Aspirin and Hydralazine, by increasing the expression of its target gene, it may increase the expression of oncoprotein BMI-1 and suppress the expression of tumor suppressor and the ageing marker INK4a/p16 (figure 1 ).
Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility.
Thus, (1) by treating myocardial patients with Aspirin and Hydralazine, one may prevent Dilated cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function; and (2) pharmacological formulations encompassing “Aspirin and Hydralazine or their analogues, either alone or in combination with any of the known drugs that are used to treat cardiomyopathy” may be used to inhibit dilated cardiomyopathy and heart failure (figure 1).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How a therapeutic mix encompassing Aspirin and Hydralazine increases the expression of oncoprotein BMI-1
# Research cooperation
For purchase and payment details, you may reach us at firstname.lastname@example.org
Web: http://genomediscovery.org or newbioideas.com
Citation: Boominathan, L., Cardiac rejuvenation therapy: A therapeutic mix encompassing Aspirin and Hydralazine suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 3/February/2018, 12.20 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com